Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target

29 Mar 2012

• By Paul Bonanos

Related Content

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

08 Nov 2011

With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise

27 Jan 2012

With Lilly Out, Amylin’s Future Is Tied To <em>Bydureon</em>

30 Nov 2011

Related Companies

Bristol Myers Squibb Company

Novo Nordisk A/S

Bristol Myers Squibb Company

AstraZeneca PLC

Eli Lilly and Company

Boehringer Ingelheim GmbH

Novartis AG

Takeda Pharmaceutical Co. Ltd.

GSK plc

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

United States Deals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.